<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">35029046</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2052-1707</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Pharmacology research &amp; perspectives</Title><ISOAbbreviation>Pharmacol Res Perspect</ISOAbbreviation></Journal><ArticleTitle>"LONG COVID"-A hypothesis for understanding the biological basis and pharmacological treatment strategy.</ArticleTitle><Pagination><StartPage>e00911</StartPage><MedlinePgn>e00911</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e00911</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/prp2.911</ELocationID><Abstract><AbstractText>Infection of humans with SARS-CoV-2 virus causes a disease known colloquially as "COVID-19" with symptoms ranging from asymptomatic to severe pneumonia. Initial pathology is due to the virus binding to the ACE-2 protein on endothelial cells lining blood vessels and entering these cells in order to replicate. Viral replication causes oxidative stress due to elevated levels of reactive oxygen species. Many (~60%) of the infected people appear to have eliminated the virus from their body after 28&#xa0;days and resume normal activity. However, a significant proportion (~40%) experience a variety of symptoms (loss of smell and/or taste, fatigue, cough, aching pain, "brain fog," insomnia, shortness of breath, and tachycardia) after 12&#xa0;weeks and are diagnosed with a syndrome named "LONG COVID." Longitudinal clinical studies in a group of subjects who were infected with SARS-CoV-2 have been compared to a non-infected matched group of subjects. A cohort of infected subjects can be identified by a battery of cytokine markers to have persistent, low level grade of inflammation and often self-report two or more troubling symptoms. There is no drug that will relieve their symptoms effectively. It is hypothesized that drugs that activate the intracellular transcription factor, nuclear factor erythroid-derived 2-like 2 (NRF2) may increase the expression of enzymes to synthesize the intracellular antioxidant, glutathione that will quench free radicals causing oxidative stress. The hormone melatonin has been identified as an activator of NRF2 and a relatively safe chemical for most people to ingest chronically. Thus, it is an option for consideration of re-purposing studies in "LONG COVID" subjects experiencing insomnia, depression, fatigue, and "brain fog" but not tachycardia. Appropriately designed clinical trials are required to evaluate melatonin.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Pharmacology Research &amp; Perspectives published by John Wiley &amp; Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jarrott</LastName><ForeName>Bevyn</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-2379-0493</Identifier><AffiliationInfo><Affiliation>Florey Institute of Neuroscience &amp; Mental Health, University of Melbourne, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Head</LastName><ForeName>Richard</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-1196-0926</Identifier><AffiliationInfo><Affiliation>University of South Australia, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pringle</LastName><ForeName>Kirsty G</ForeName><Initials>KG</Initials><Identifier Source="ORCID">0000-0002-6770-0496</Identifier><AffiliationInfo><Affiliation>School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, Newcastle, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lumbers</LastName><ForeName>Eugenie R</ForeName><Initials>ER</Initials><Identifier Source="ORCID">0000-0003-3945-3923</Identifier><AffiliationInfo><Affiliation>School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, Newcastle, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Jennifer H</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0002-8614-0199</Identifier><AffiliationInfo><Affiliation>Centre for Drug Repurposing and Medicines Research, Clinical Pharmacology, University of Newcastle, New Lambton, New South Wales, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pharmacol Res Perspect</MedlineTA><NlmUniqueID>101626369</NlmUniqueID><ISSNLinking>2052-1707</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004730" MajorTopicYN="N">Endothelium, Vascular</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">NRF2</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">endothelium</Keyword><Keyword MajorTopicYN="N">melatonin</Keyword><Keyword MajorTopicYN="N">oxidative stress</Keyword><Keyword MajorTopicYN="N">tissue hypoxia</Keyword><Keyword MajorTopicYN="N">&#x201c;LONG COVID&#x201d;</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35029046</ArticleId><ArticleId IdType="pmc">PMC8929332</ArticleId><ArticleId IdType="doi">10.1002/prp2.911</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Servidio C, Stellacci F. Therapeutic approaches against coronaviruses acute respiratory syndrome. Pharmacol Res Perspect. 2021;9(1):e00691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7773137</ArticleId><ArticleId IdType="pubmed">33378565</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xfc;scher TF. Understanding COVID&#x2010;19: in the end it is the endothelium&#x2010;what else? Eur Heart J. 2020;41(32):3023&#x2010;3027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7499643</ArticleId><ArticleId IdType="pubmed">33216863</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalish H, Klumpp&#x2010;Thomas C, Hunsberger S, et al. Undiagnosed SARS&#x2010;CoV&#x2010;2 seropositivity during the first 6 months of the COVID&#x2010;19 pandemic in the United States. Sci Transl Med. 2021;13(601):eabh3826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8432952</ArticleId><ArticleId IdType="pubmed">34158410</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodin P. Immune determinants of COVID&#x2010;19 disease presentation and severity. Nat Med. 2021;27(1):28&#x2010;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">33442016</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul BD, Lemle MD, Komaroff AL, Snyder SH. Redox imbalance links COVID&#x2010;19 and myalgic encephalomyelitis/chronic fatigue syndrome. Proc Natl Acad Sci USA. 2021;118(34):e2024358118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8403932</ArticleId><ArticleId IdType="pubmed">34400495</ArticleId></ArticleIdList></Reference><Reference><Citation>Kass DA, Duggal P, Cingolani O. Obesity could shift severe COVID&#x2010;19 disease to younger ages. Lancet. 2020;395(10236):1544&#x2010;1545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7196905</ArticleId><ArticleId IdType="pubmed">32380044</ArticleId></ArticleIdList></Reference><Reference><Citation>Accessed 10 Aug 2021. https://www.nice.org.uk/news/article/nice&#x2010;rcgp&#x2010;and&#x2010;sign&#x2010;publish&#x2010;guideline&#x2010;on&#x2010;managing&#x2010;the&#x2010;long&#x2010;term&#x2010;effects&#x2010;of&#x2010;covid&#x2010;19
</Citation></Reference><Reference><Citation>Nabavi N. Long COVID: how to define it and how to manage it. BMJ. 2020;7(370):m3489.</Citation><ArticleIdList><ArticleId IdType="pubmed">32895219</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C, Valdes AM, Freidin MB, et al. Real&#x2010;time tracking of self&#x2010;reported symptoms to predict potential COVID&#x2010;19. Nat Med. 2020;26(7):1037&#x2010;1040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7751267</ArticleId><ArticleId IdType="pubmed">32393804</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin&#x2010;Chowdhury Z, Ladhani SN. Causation or confounding: why controls are critical for characterizing long COVID. Nat Med. 2021;27(7):1129&#x2010;1130.</Citation><ArticleIdList><ArticleId IdType="pubmed">34140704</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayres JS. A metabolic handbook for the COVID&#x2010;19 pandemic. Nat Metab. 2020;2(7):572&#x2010;585.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7325641</ArticleId><ArticleId IdType="pubmed">32694793</ArticleId></ArticleIdList></Reference><Reference><Citation>Sykes DL, Holdsworth L, Jawad N, et al. Post&#x2010;COVID&#x2010;19 symptom burden: what is Long&#x2010;COVID and how should we manage it? Lung. 2021;199(2):113&#x2010;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7875681</ArticleId><ArticleId IdType="pubmed">33569660</ArticleId></ArticleIdList></Reference><Reference><Citation>Darley DR, Dore GJ, Byrne AL, et al. Limited recovery from post&#x2010;acute sequelae of SARS&#x2010;CoV&#x2010;2 at 8 months in a prospective cohort. ERJ Open Res. 2021;7(4):00384&#x2010;2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8504133</ArticleId><ArticleId IdType="pubmed">34725634</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley GJ, Wilson DB, et al. Immunological dysfunction persists for 8 months following initial mild&#x2010;moderate SARS&#x2010;CoV&#x2010;2 infection. Nat Immunol. 2022;23:in press.</Citation><ArticleIdList><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg B, Mohn K&#x2010;I, Brokstad KA, et al. Long COVID in a prospective cohort of home&#x2010;isolated patients. Nat Med. 2021;27(9):1607&#x2010;1613. doi:10.1038/s41591-021-01433-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01433-3</ArticleId><ArticleId IdType="pmc">PMC8440190</ArticleId><ArticleId IdType="pubmed">34163090</ArticleId></ArticleIdList></Reference><Reference><Citation>Radin JM, Quer G, Ramos E, et al. Assessment of prolonged physiological and behavioral changes associated with COVID&#x2010;19 infection. JAMA Netw Open. 2021;4(7):e2115959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8264646</ArticleId><ArticleId IdType="pubmed">34232306</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. Post&#x2010;acute COVID&#x2010;19 syndrome. Nat Med. 2021;27(4):601&#x2010;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Libby P, L&#xfc;scher T. COVID&#x2010;19 is, in the end, an endothelial disease. Eur Heart J. 2020;41(32):3038&#x2010;3044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7470753</ArticleId><ArticleId IdType="pubmed">32882706</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid&#x2010;19. N Engl J Med. 2020;383(2):120&#x2010;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7412750</ArticleId><ArticleId IdType="pubmed">32437596</ArticleId></ArticleIdList></Reference><Reference><Citation>Armulik A, Genov&#xe9; G, Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell. 2011;21(2):193&#x2010;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">21839917</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Yang Y, Fan X. Microvascular pericytes in brain&#x2010;associated vascular disease. Biomed Pharmacother. 2020;121:109633.</Citation><ArticleIdList><ArticleId IdType="pubmed">31743876</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd8;stergaard L. SARS CoV&#x2010;2 related microvascular damage and symptoms during and after COVID&#x2010;19: consequences of capillary transit&#x2010;time changes, tissue hypoxia and inflammation. Physiol Rep. 2021;9(3):e14726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7849453</ArticleId><ArticleId IdType="pubmed">33523608</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall M. COVID and the brain: researchers zero in on how damage occurs. Nature. 2021;595(7868):484&#x2010;485.</Citation><ArticleIdList><ArticleId IdType="pubmed">34234323</ArticleId></ArticleIdList></Reference><Reference><Citation>Brann DH, Tsukahara T, Weinreb C, et al. Non&#x2010;neuronal expression of SARS&#x2010;CoV&#x2010;2 entry genes in the olfactory system suggests mechanisms underlying COVID&#x2010;19&#x2010;associated anosmia. Sci Adv. 2020;6(31):eabc5801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10715684</ArticleId><ArticleId IdType="pubmed">32937591</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribeiro DE, Oliveira&#x2010;Giacomelli &#xc1;, Glaser T, et al. Hyperactivation of P2X7 receptors as a culprit of COVID&#x2010;19 neuropathology. Mol Psychiatry. 2021;26(4):1044&#x2010;1059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7738776</ArticleId><ArticleId IdType="pubmed">33328588</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Xu J, Hou Y, et al. Network medicine links SARS&#x2010;CoV&#x2010;2/COVID&#x2010;19 infection to brain microvascular injury and neuroinflammation in dementia&#x2010;like cognitive impairment. Alzheimers Res Ther. 2021;13(1):110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8189279</ArticleId><ArticleId IdType="pubmed">34108016</ArticleId></ArticleIdList></Reference><Reference><Citation>Checconi P, De Angelis M, Marcocci ME, et al. Redox&#x2010;modulating agents in the treatment of viral infections. Int J Mol Sci. 2020;21(11):4084.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7312898</ArticleId><ArticleId IdType="pubmed">32521619</ArticleId></ArticleIdList></Reference><Reference><Citation>
Basic leucine zipper domain TFs. http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyid=1019
</Citation></Reference><Reference><Citation>Ratajczak MZ, Kucia M. SARS&#x2010;CoV&#x2010;2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine "storm" and risk factor for damage of hematopoietic stem cells. Leukemia. 2020;34(7):1726&#x2010;1729.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7262681</ArticleId><ArticleId IdType="pubmed">32483300</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratajczak MZ, Bujko K, Ciechanowicz A, et al. SARS&#x2010;CoV&#x2010;2 entry receptor ACE2 is expressed on very small CD45&#x2010; precursors of hematopoietic and endothelial cells and in response to virus spike protein activates the Nlrp3 inflammasome. Stem Cell Rev Rep. 2021;17(1):266&#x2010;277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7370872</ArticleId><ArticleId IdType="pubmed">32691370</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren X&#x2010;S, Tong Y, Ling LI, et al. NLRP3 gene deletion attenuates angiotensin II&#x2010;induced phenotypic transformation of vascular smooth muscle cells and vascular remodeling. Cell Physiol Biochem. 2017;44(6):2269&#x2010;2280.</Citation><ArticleIdList><ArticleId IdType="pubmed">29262411</ArticleId></ArticleIdList></Reference><Reference><Citation>Lumbers ER, Head R, Smith G, et al. The interacting physiology of COVID&#x2010;19 and the renin&#x2010;angiotensin&#x2010;aldosterone system: key agents for treatment. Pharmacol Res Perspect. 2022; in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8929333</ArticleId><ArticleId IdType="pubmed">35106954</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodson M, de la Vega MR, Cholanians AB, Schmidlin CJ, Chapman E, Zhang DD. Modulating NRF2 in disease: timing is everything. Annu Rev Pharmacol Toxicol. 2019;6(59):555&#x2010;575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6538038</ArticleId><ArticleId IdType="pubmed">30256716</ArticleId></ArticleIdList></Reference><Reference><Citation>Jhang JJ, Yen GC. The role of NRF2 in NLRP3 inflammasome activation. Cell Mol Immunol. 2017;14(12):1011&#x2010;1012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719138</ArticleId><ArticleId IdType="pubmed">29129911</ArticleId></ArticleIdList></Reference><Reference><Citation>Hennig P, Garstkiewicz M, Grossi S, Di Filippo M, French L, Beer H&#x2010;D. The crosstalk between NRF2 and inflammasomes. Int J Mol Sci. 2018;19(2):562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5855784</ArticleId><ArticleId IdType="pubmed">29438305</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai Z, Zhao X, Li C, Sheng C, Li H. EV71 virus reduces NRF2 activation to promote production of reactive oxygen species in infected cells. Gut Pathog. 2020;23(12):22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7181592</ArticleId><ArticleId IdType="pubmed">32346399</ArticleId></ArticleIdList></Reference><Reference><Citation>Head R, Lumbers ER, Jarrott B, et al. Systems analysis shows that thermodynamic, physiological and pharmacological fundamentals drive COVID&#x2010;19 and response to treatment. Pharmacol Res Perspect. 2022; in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8929328</ArticleId><ArticleId IdType="pubmed">35106955</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin JH, Head R. Obesity and COVID&#x2010;19: renin&#x2010;angiotensin as a mediator of morbidity and mortality. Br J Nutr. 2021;3:1&#x2010;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8376908</ArticleId><ArticleId IdType="pubmed">34078498</ArticleId></ArticleIdList></Reference><Reference><Citation>Anker SD, Coats AJS. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol. 2002;86(2&#x2010;3):123&#x2010;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">12419548</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma A, Rizky L, Stefanovic N, et al. The nuclear factor (erythroid&#x2010;derived 2)&#x2010;like 2 (NRF2) activator dh404 protects against diabetes&#x2010;induced endothelial dysfunction. Cardiovasc Diabetol. 2017;16(1):33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5335831</ArticleId><ArticleId IdType="pubmed">28253885</ArticleId></ArticleIdList></Reference><Reference><Citation>Angulo J, El Assar M, Sevilleja&#x2010;Ortiz A, et al. Short&#x2010;term pharmacological activation of NRF2 ameliorates vascular dysfunction in aged rats and in pathological human vasculature. A potential target for therapeutic intervention. Redox Biol. 2019;26:101271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6626891</ArticleId><ArticleId IdType="pubmed">31302408</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L, Zhang H, Davies KJ, Forman HJ. Aging&#x2010;related decline in the induction of NRF2&#x2010;regulated antioxidant genes in human bronchial epithelial cells. Redox Biol. 2018;14(1):35&#x2010;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5576992</ArticleId><ArticleId IdType="pubmed">28863281</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinkova&#x2010;Kostova AT, Holtzclaw WD, Kensler TW. The role of Keap1 in cellular protective responses. Chem Res Toxicol. 2005;18(12):1779&#x2010;1791.</Citation><ArticleIdList><ArticleId IdType="pubmed">16359168</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardinali DP, Brown GM, Pandi&#x2010;Perumal SR. Can melatonin be a potential "Silver Bullet" in treating COVID&#x2010;19 patients? Diseases. 2020;8(4):44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7709121</ArticleId><ArticleId IdType="pubmed">33256258</ArticleId></ArticleIdList></Reference><Reference><Citation>Arioz BI, Tastan B, Tarakcioglu E, et al. Melatonin attenuates LPS&#x2010;induced acute depressive&#x2010;like behaviors and microglial NLRP3 inflammasome activation through the SIRT1/NRF2 pathway. Front Immunol. 2019;2(10):1511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6615259</ArticleId><ArticleId IdType="pubmed">31327964</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhdanova IV, Lynch HJ, Wurtman RJ. Melatonin: a sleep&#x2010;promoting hormone. Sleep. 1997;20(10):899&#x2010;907.</Citation><ArticleIdList><ArticleId IdType="pubmed">9415953</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashrafizadeh M, Najafi M, Kavyiani N, Mohammadinejad R, Farkhondeh T, Samarghandian S. Anti&#x2010;inflammatory activity of melatonin: a focus on the role of NLRP3 inflammasome. Inflammation. 2021;44(4):1207&#x2010;1222.</Citation><ArticleIdList><ArticleId IdType="pubmed">33651308</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernando S, Rombauts L. Melatonin: shedding light on infertility?&#x2010;a review of the recent literature. J Ovarian Res. 2014;21(7):98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4209073</ArticleId><ArticleId IdType="pubmed">25330986</ArticleId></ArticleIdList></Reference><Reference><Citation>Ejaz H, Figaro JK, Woolner AMF, Thottakam BMV, Galley HF. Maternal serum melatonin Increases during pregnancy and falls immediately after delivery implicating the placenta as a major source of melatonin. Front Endocrinol. 2021;18(11):623038.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7930478</ArticleId><ArticleId IdType="pubmed">33679607</ArticleId></ArticleIdList></Reference><Reference><Citation>Guardiola&#x2010;Lema&#xee;tre B. Toxicology of melatonin. J Biol Rhythms. 1997;12(6):697&#x2010;706.</Citation><ArticleIdList><ArticleId IdType="pubmed">9406047</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt J. Safety of melatonin in long&#x2010;term use (?). J Biol Rhythms. 1997;12(6):673&#x2010;681.</Citation><ArticleIdList><ArticleId IdType="pubmed">9406044</ArticleId></ArticleIdList></Reference><Reference><Citation>Vriend J, Reiter RJ. The Keap1&#x2010;NRF2&#x2010;antioxidant response element pathway: a review of its regulation by melatonin and the proteasome. Mol Cell Endocrinol. 2015;5(401):213&#x2010;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">25528518</ArticleId></ArticleIdList></Reference><Reference><Citation>Melhuish Beaupre LM, Brown GM, Gon&#xe7;alves VF, Kennedy JL. Melatonin's neuroprotective role in mitochondria and its potential as a biomarker in aging, cognition and psychiatric disorders. Transl Psychiatry. 2021;11(1):339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8172874</ArticleId><ArticleId IdType="pubmed">34078880</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlachou M, Siamidi A, Dedeloudi A, Konstantinidou S, Papanastasiou I. Pineal hormone melatonin as an adjuvant treatment for COVID&#x2010;19 (Review). Int J Mol Med. 2021;47(4):47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7891824</ArticleId><ArticleId IdType="pubmed">33576451</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowes DA, Thottakam BMV, Webster NR, Murphy MP, Galley HF. The mitochondria&#x2010;targeted antioxidant MitoQ protects against organ damage in a lipopolysaccharide&#x2010;peptidoglycan model of sepsis. Free Radic Biol Med. 2008;45(11):1559&#x2010;1565.</Citation><ArticleIdList><ArticleId IdType="pubmed">18845241</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowes DA, Almawash AM, Webster NR, Reid Vl, Galley HF. Melatonin and structurally similar compounds have differing effects on inflammation and mitochondrial function in endothelial cells under conditions mimicking sepsis. Br J Anaesth. 2011;107(2):193&#x2010;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">21659405</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowes DA, Webster NR, Murphy MP, Galley HF. Antioxidants that protect mitochondria reduce interleukin&#x2010;6 and oxidative stress, improve mitochondrial function, and reduce biochemical markers of organ dysfunction in a rat model of acute sepsis. Br J Anaesth. 2013;110(3):472&#x2010;480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3570068</ArticleId><ArticleId IdType="pubmed">23381720</ArticleId></ArticleIdList></Reference><Reference><Citation>Galley HF, Lowes DA, Allen L, Cameron G, Aucott LS, Webster NR. Melatonin as a potential therapy for sepsis: a phase I dose escalation study and an ex vivo whole blood model under conditions of sepsis. J Pineal Res. 2014;56(4):427&#x2010;438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4279949</ArticleId><ArticleId IdType="pubmed">24650045</ArticleId></ArticleIdList></Reference><Reference><Citation>McCreath G, Scullion MM, Lowes DA, Webster NR, Galley HF. Pharmacological activation of endogenous protective pathways against oxidative stress under conditions of sepsis. Br J Anaesth. 2016;116(1):131&#x2010;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">26675956</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xed;ctor VM, Espulgues JV, Hern&#xe1;ndez&#x2010;Mijares A, Rocha M. Oxidative stress and mitochondrial dysfunction in sepsis: a potential therapy with mitochondria&#x2010;targeted antioxidants. Infect Disord Drug Targets. 2009;9(4):376&#x2010;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">19689380</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMuro RL, Nafziger AN, Blask DE, Menhinick AM, Bertino JS. The absolute bioavailability of oral melatonin. J Clin Pharmacol. 2000;40(7):781&#x2010;784.</Citation><ArticleIdList><ArticleId IdType="pubmed">10883420</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;n Gim&#xe9;nez VM, Prado N, Diez E, Diez E, Manucha W, Reiter RJ. New proposal involving nanoformulated melatonin targeted to the mitochondria as a potential COVID&#x2010;19 treatment. Nanomedicine. 2020;15(29):2819&#x2010;2821.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7720650</ArticleId><ArticleId IdType="pubmed">33269948</ArticleId></ArticleIdList></Reference><Reference><Citation>Cross KM, Landis DM, Sehgal L, Payne JD. Melatonin for the early treatment of COVID&#x2010;19: a narrative review of current evidence and possible efficacy. Endocr Pract. 2021;27(8):850&#x2010;855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8190272</ArticleId><ArticleId IdType="pubmed">34119679</ArticleId></ArticleIdList></Reference><Reference><Citation>Zisapel N. New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation. Br J Pharmacol. 2018;175(16):3190&#x2010;3199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6057895</ArticleId><ArticleId IdType="pubmed">29318587</ArticleId></ArticleIdList></Reference><Reference><Citation>Thottakam BMVJ, Webster NR, Allen L, Columb MO, Galley HF. Melatonin Is a feasible, safe, and acceptable intervention in doctors and nurses working nightshifts: the MIDNIGHT Trial. Front Psychiatry. 2020;27(11):872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7481467</ArticleId><ArticleId IdType="pubmed">33192634</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanford SC. Recent developments in research of melatonin and its potential therapeutic applications. Br J Pharmacol. 2018;175(16):3187&#x2010;3189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6057894</ArticleId><ArticleId IdType="pubmed">30917240</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardinali DP, Srinivasan V, Brzezinski A, Brown GM. Melatonin and its analogs in insomnia and depression. J Pineal Res. 2012;52(4):365&#x2010;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">21951153</ArticleId></ArticleIdList></Reference><Reference><Citation>Satyanarayanan SK, Su H, Lin YW, Su KP. Circadian rhythm and melatonin in the treatment of depression. Curr Pharm Des. 2018;24(22):2549&#x2010;2555.</Citation><ArticleIdList><ArticleId IdType="pubmed">30073921</ArticleId></ArticleIdList></Reference><Reference><Citation>Vald&#xe9;s&#x2010;Tovar M, Estrada&#x2010;Reyes R, Sol&#xed;s&#x2010;Chagoy&#xe1;n H, et al. Circadian modulation of neuroplasticity by melatonin: a target in the treatment of depression. Br J Pharmacol. 2018;175(16):3200&#x2010;3208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6057892</ArticleId><ArticleId IdType="pubmed">29512136</ArticleId></ArticleIdList></Reference><Reference><Citation>Estrada&#x2010;Reyes R, Vald&#xe9;s&#x2010;Tovar M, Arrieta&#x2010;Baez D, et al. The timing of melatonin administration is crucial for its antidepressant&#x2010;like effect in mice. Int J Mol Sci. 2018;19(8):2278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6121277</ArticleId><ArticleId IdType="pubmed">30081472</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivan M, Rayner C, Delaney B. Fresh evidence of the scale and scope of long COVID. BMJ. 2021;373:n853.</Citation><ArticleIdList><ArticleId IdType="pubmed">33795224</ArticleId></ArticleIdList></Reference><Reference><Citation>Accessed December 23, 2021. https://www.cuh.nhs.uk/news/national&#x2010;drug&#x2010;trial&#x2010;to&#x2010;prevent&#x2010;deaths&#x2010;after&#x2010;covid&#x2010;patients&#x2010;leave&#x2010;hospital/
</Citation></Reference><Reference><Citation>Satoh M, Takahashi Y, Tabuchi T, et al. Cellular and molecular mechanisms of statins: an update on pleiotropic effects. Clin Sci. 2015;129(2):93&#x2010;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">25927679</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandra A, Chakraborty U, Ghosh S, Dasgupta S. Anticoagulation in COVID&#x2010;19: current concepts and controversies. Postgrad Med J. 2021;postgradmedj&#x2010;2021&#x2010;139923.</Citation><ArticleIdList><ArticleId IdType="pubmed">33850011</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper SL, Boyle E, Jefferson SR, et al. Role of the renin&#x2010;angiotensin&#x2010;aldosterone and kinin&#x2010;kallikrein systems in the cardiovascular complications of COVID&#x2010;19 and long COVID. Int J Mol Sci. 2021;22(15):8255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8347967</ArticleId><ArticleId IdType="pubmed">34361021</ArticleId></ArticleIdList></Reference><Reference><Citation>Harding SD, Sharman JL, Faccenda E, et al.; NC&#x2010;IUPHAR . The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucleic Acids Res. 2018;46(D1):D1091&#x2010;D1106. doi:10.1093/nar/gkx1121</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx1121</ArticleId><ArticleId IdType="pmc">PMC5753190</ArticleId><ArticleId IdType="pubmed">29149325</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander SPH, Kelly E, Mathie A, et al.; CGTP Collaborators . THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: introduction and other protein targets. Br J Pharmacol. 2019;176(Suppl 1):S1&#x2010;S20. doi:10.1111/bph.14747</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.14747</ArticleId><ArticleId IdType="pmc">PMC6844537</ArticleId><ArticleId IdType="pubmed">31710719</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>